covid
Buscar en
Endocrinología y Nutrición (English Edition)
Toda la web
Inicio Endocrinología y Nutrición (English Edition) Malignant glucagonoma: An uncommon cause of new onset diabetes
Journal Information
Vol. 58. Issue 4.
Pages 199-201 (April 2011)
Share
Share
Download PDF
More article options
Vol. 58. Issue 4.
Pages 199-201 (April 2011)
Scientific Letter
Full text access
Malignant glucagonoma: An uncommon cause of new onset diabetes
Glucagonoma maligno como causa infrecuente de diabetes de inicio
Visits
1612
Raquel Guerrero Vázqueza,
Corresponding author
, Rosario Oliva Rodrígueza, Juan Ignacio Cuenca Cuencab, Felicia Sánchez Alberdic, Elena Navarro Gonzáleza
a Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Instituto de Investigación Biomédica de Sevilla, Sevilla, Spain
b Unidad de Gestión Clínica de Medicina Nuclear, Hospital Universitario Virgen del Rocío, Instituto de Investigación Biomédica de Sevilla, Sevilla, Spain
c Servicio de Anatomía Patológica, Hospital Universitario Virgen del Rocío, Instituto de Investigación Biomédica de Sevilla, Sevilla, Spain
This item has received
Article information
Full text is only aviable in PDF
References
[1.]
H. Kindmark, A. Sundin, D. Grandberg, K. Dunden, B. Skogseid, E.T. Janson, et al.
Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years.
Med Oncol, 24 (2007), pp. 330-337
[2.]
A.P. Van Beek, E.R.M. de Haas, W.A. van Vloten, C.J.M. Lips, J.F.M. Roijers, M.R. Canninga-van Dijk.
The glucogonoma syndrome and necrolytic migratory erythema: a clinical review.
Eur J Endocrinol, 151 (2004), pp. 531-537
[3.]
R.A. Wermers, V. Fatourechi, A.G. Wynne, L.K. Kvols, R.V. Lloyd.
The glucagonoma syndrome: clinical and pathology features in 21 patients.
Medicine, 75 (1996), pp. 53-63
[4.]
M. Echenique-Elizondo, A. Tuneu, J.L. Elorza, I. Martínez de Lizardury, J. Ibáñez.
Síndrome del glucagonoma y seudoglucagonoma.
Cir Esp, 76 (2004), pp. 318-324
[5.]
R. Pujol, C.E. Wang, R.A. el-Azhary, W.P.D. Su, L.E. Gibson, A.L. Schroeter.
Necrolytic migratory erythema: clinicopathologic study of 13 cases.
Int J Dermatol, 43 (2004), pp. 12-18
[6.]
E. Vauleon, J. Egreteau, E. Boucher, V. Desfourneaux, J.F. Bretagne, J.L. Raoul.
Glucagonoma: a recent series of 7 cases.
Bull Cancer, 91 (2004), pp. 637-640
[7.]
A.I. Vinik, E.A. Woltering, R.P.P. Warner, M. Caplin, T.M. O’Dorisio, G.A. Wiseman, et al.
NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor.
Pancreas, 39 (2010), pp. 713-734
[8.]
A. Rinke, H.H. Müller, C. Schade-Brittinger, K.J. Klose, P. Barth, M. Wied, et al.
PROMID Study Group. Placebo-controlled, doubleblind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
J Clin Oncol, 27 (2009), pp. 4656-4663
[9.]
J.C. Yao, C. Lombard-Bohas, E. Baudin, L.K. Kvols, P. Rougier, P. Ruszniewski, et al.
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
J Clin Oncol, 28 (2010), pp. 69-676
[10.]
K.Y. Bilimoria, M.S. Talamonti, J.S. Tomlinson, A.K. Stewart, D.P. Winchester, C.Y. Ko, et al.
Pronostic score predicting suvival after resection of pancreatic neuroendocrine tumors.
Ann Surg, 247 (2008), pp. 490-500
Copyright © 2011. Sociedad Española de Endocrinología y Nutrición
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos